[NMusers] Apply now for the first advanced DDMoRe course in Oncology : 4-8 July 2016 UniversitÓ degli Studi di Pavia, Italy

From: Cheung, Amy <Amy.Cheung_at_astrazeneca.com>
Date: Fri, 6 May 2016 10:23:09 +0000

Model-informed Drug Development in Oncology (advanced)
Apply here for DDMoRe Oncology (advanced)
http://www.ddmore.eu/projects/model-informed-drug-development-oncology-adva=
nced

The DDMoRe consortium concludes the series of comprehensive face-to-face co=
urses with the first advanced course introducing the principles of model-in=
formed drug development, covering a range of therapeutic areas, via the new=
ly-developed DDMoRe interoperability framework platform. The Bioinformatics=
, Mathematical Modeling and Synthetic Biology (BMS) lab at UniversitÓ deg=
li Studi di Pavia, Italy and the Institute of Pharmacy, Freie Universitaet =
Berlin, Germany are happy to invite you to the following face-to-face cours=
e:

"Model-informed Drug Development in Oncology (advanced)"

Dates: 4-8 July 2016

Venue: Departement of Electrical, Computer and Biomedical Engineering, Univ=
ersitÓ degli Studi di Pavia, Via Ferrata 5, Pavia, Italy

Intended for: PhD students and Postdoctoral fellows doing research in the q=
uantitative life sciences field as well as other scientists in the field.

Topics: Model-informed drug development in the area of oncology with a 2-da=
y and half introduction to the DDMoRe platform (new modelling & simulation =
language, model repository, interoperability framework) and 2-day and half =
application of the DDMoRe platform to therapeutic area oncology

Program: Lectures, hands-on sessions, group work, workshops, and participan=
t presentations

Course directors: Charlotte Kloft (Freie Universitaet Berlin, Germany), Pao=
lo Magni (UniversitÓ degli Studi di Pavia, Italy), Zinnia Parra-GuillÚn=
 (Freie Universitaet Berlin, Germany/University of Navarra, Pamplona, Spain=
), Lorenzo Pasotti (UniversitÓ degli Studi di Pavia, Italy)

Prerequisites:
* Willing to actively participate in the course and give constructive feedb=
ack to further improve the DDMoRe products and developments
* Able to bring along a laptop that fulfils the minimum IT environment requ=
irements specified here.

Fee: Free of charge (transport, accommodation and food not included) Maximu=
m number of participants: 20 (If needed selection based on the registration=
 information, with priority to PhD students/post-docs and participants from=
 different institutions).

Application deadline: 25th May 2016 (Notification of acceptance 31st May 20=
16)

Contact: ddmore_OncoAdv_at_aimed11.unipv.it<mailto:ddmore_OncoAdv_at_aimed11.unip=
v.it>

For more information:
* DDMoRe and the 'education & training activities': http://www.ddmore.eu
* BMS lab: http://lab-bioinfo.unipv.it
* About the Clinical Pharmacy group at the FU Berlin: http://www.bcp.fu-ber=
lin.de/pharmazie/klinische_pharmazie/arbeitsgruppe_kloft/index.html
* UNIPV: http://www.unipv.it

We warmly invite you to join us for the last public DDMoRe course: be the f=
irst trained for using the most advanced DDMoRe products!

Please download and save the application form on the DDMoRe web page, befor=
e you fill-in and submit to: ddmore_OncoAdv_at_aimed11.unipv.it<mailto:ddmore_=
OncoAdv_at_aimed11.unipv.it>

________________________________

AstraZeneca UK Limited is a company incorporated in England and Wales with =
registered number:03674842 and its registered office at 1 Francis Crick Ave=
nue, Cambridge Biomedical Campus, Cambridge, CB2 0AA.

This e-mail and its attachments are intended for the above named recipient =
only and may contain confidential and privileged information. If they have =
come to you in error, you must not copy or show them to anyone; instead, pl=
ease reply to this e-mail, highlighting the error to the sender and then im=
mediately delete the message. For information about how AstraZeneca UK Limi=
ted and its affiliates may process information, personal data and monitor c=
ommunications, please see our privacy notice at www.astrazeneca.com<https:/=
/www.astrazeneca.com>

Received on Fri May 06 2016 - 06:23:09 EDT

This archive was generated by hypermail 2.3.0 : Fri Sep 27 2019 - 16:50:24 EDT